Fortrea Holdings Inc. Common Stock FTRE

Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.

• GlobeNewswire Inc. 3 sept

  Fortrea Akan Mengakuisisi Unit Farmakologi Klinis dan Operasional Laboratorium Bionalitik dari Worldwide Clinical Trials

  Fortrea has signed a definitive agreement to acquire the Early Phase Services division from Worldwide Clinical Trials for approximately $45 million. The acquisition includes bioanalytical laboratories in Austin, a 200-bed clinical pharmacology unit in San Antonio, and biospeci­men storage facilities in Pflugerville, Texas. This deal strengthens Fortrea's early-stage clinical development platform and integrated capabilities, while allowing Worldwide to focus on its faster-growing late-stage business across oncology, neuroscience, and rare diseases.

  

• GlobeNewswire Inc. 3 sept

  Fortrea Adquire Unidade de Farmacologia Clínica e Operações de Laboratório Bioanalítico da Worldwide Clinical Trials

  Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in cash. The acquisition includes a GLP-certified bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biosampling storage facility in Pflugerville, Texas. This strategic move strengthens Fortrea's early-stage clinical development platform and enables integrated Phase I-IV services, while allowing Worldwide to focus on its rapidly growing advanced-stage development business in oncology, neurociencia, and rare diseases.

  

• GlobeNewswire Inc. 3 sept

  フォートリア、ワールドワイド・クリニカル・トライアルズから臨床薬理部門およびバイオアナリシスラボ事業を買収

  Fortrea has entered into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biorepository facility in Pflugerville, Texas. This strategic move strengthens Fortrea's end-to-end clinical development platform from Phase I through Phase IV trials, while allowing Worldwide to focus on its rapidly growing late-stage business in oncology, neuroscience, internal medicine, and rare diseases.

  

• GlobeNewswire Inc. 3 sept

  Fortrea übernimmt Einheit für klinische Pharmakologie und bioanalytische Laboraktivitäten von Worldwide Clinical Trials

  Fortrea hat eine verbindliche Vereinbarung zum Erwerb des Geschäftsbereichs 'Frühe klinische Entwicklung' von Worldwide Clinical Trials für etwa 45 Millionen US-Dollar abgeschlossen. Die Übernahme umfasst ein GLP-konformes bioanalytisches Labor in Austin, eine klinisch-pharmakologische Abteilung mit 200 Betten in San Antonio und ein Bioprobenlager in Texas. Dies stärkt Fortreas Position als führender globaler Partner für klinische Entwicklung und ermöglicht integrierte Lösungen für frühe klinische Phasen.

  

• GlobeNewswire Inc. 3 sept

  Fortrea acquiert l’unité de pharmacologie clinique et les activités de laboratoire bioanalytique de Worldwide Clinical Trials

  Fortrea has agreed to acquire the Early Phase Services division of Worldwide Clinical Trials for approximately $45 million in an all-cash transaction. The acquisition includes a GLP-compliant bioanalytical laboratory in Austin, a 200-bed clinical pharmacology unit in San Antonio, and a biological sample storage facility in Pflugerville, Texas. This strengthens Fortrea's end-to-end clinical development platform with integrated bioanalytical capabilities for both large and small molecules, while allowing Worldwide to focus on its growing advanced-stage development activities in oncology, neurosciences, internal medicine, and rare diseases.